© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 90739 refers to the Hepatitis B vaccine (HepB), specifically the CpG-adjuvanted formulation intended for adult use. This vaccine is administered intramuscularly and is available in either a 2-dose or a 4-dose schedule. Unlike immune globulins, which offer short-term, passive immunity, vaccines like the Hepatitis B vaccine provide active, long-term immunity. This is achieved by exposing the recipient's immune system to modified versions of the hepatitis B virus, prompting the immune system to produce its own antibodies. As a result, the body retains the ability to generate these antibodies upon subsequent exposure to the virus, thereby offering protection against hepatitis B, a chronic liver disease that can lead to severe health complications, including hospitalization and death. The Hepatitis B vaccine is significant not only for its role in preventing the disease but also for its potential to avert long-term consequences such as hepatocellular carcinoma, making it one of the pioneering cancer vaccines in clinical use. The vaccine can be derived from the blood plasma of asymptomatic carriers or produced through recombinant technology, where a plasmid containing the hepatitis gene is inserted into common baker's yeast. This yeast is then lysed, and the components are purified for use in the vaccine. It is important to note that the codes associated with the Hepatitis B vaccine, including code 90739, specifically report the vaccine product itself for intramuscular administration, while the actual injection procedure is reported separately. The CpG-adjuvanted HepB vaccine represents a single antigen vaccine enhanced with a new class of stimulant designed to boost the immune response to the hepatitis B antigen.
© Copyright 2025 Coding Ahead. All rights reserved.
The Hepatitis B vaccine (HepB), CpG-adjuvanted, is indicated for the prevention of hepatitis B virus infection in adults. This vaccine is particularly important for individuals who may be at risk of exposure to the virus, which can lead to chronic liver disease, hospitalization, and even death. The vaccine is also crucial for preventing the long-term consequences associated with hepatitis B, such as hepatocellular carcinoma, thereby serving as a preventive measure against certain types of cancer.
The administration of the Hepatitis B vaccine (CPT® Code 90739) follows a structured procedure to ensure effective immunization. The vaccine is delivered intramuscularly, typically in the deltoid muscle of the upper arm. The procedure begins with the healthcare provider preparing the vaccine, ensuring that it is stored and handled according to the manufacturer's guidelines. The provider will then cleanse the injection site with an antiseptic to minimize the risk of infection. Next, the vaccine is drawn into a syringe, and the provider will select an appropriate needle size for intramuscular injection. The injection site is then held taut, and the needle is inserted at a 90-degree angle to ensure proper delivery into the muscle tissue. After the vaccine is injected, the provider will withdraw the needle swiftly and apply gentle pressure to the site with a cotton ball or gauze to control any bleeding. Finally, the provider will dispose of the needle and syringe in a sharps container and document the administration of the vaccine in the patient's medical record, including the date, vaccine lot number, and any other relevant details. It is important to note that the Hepatitis B vaccine is available in either a 2-dose or a 4-dose schedule, depending on the specific immunization protocol recommended for the patient.
After the administration of the Hepatitis B vaccine, patients are typically monitored for a short period to observe for any immediate adverse reactions, such as allergic responses. It is common for patients to experience mild side effects, including soreness at the injection site, low-grade fever, or fatigue, which usually resolve within a few days. Patients should be advised to report any unusual or severe reactions to their healthcare provider. Additionally, it is important for patients to complete the full vaccination schedule, whether it is the 2-dose or 4-dose regimen, to ensure optimal immunity against hepatitis B. Follow-up appointments may be scheduled to administer subsequent doses as needed. Patients should also be educated on the importance of maintaining their vaccination records and the potential need for booster doses in the future, depending on their risk factors and healthcare provider recommendations.
| Short Descr | HEPB VACC 2/4 DOSE ADULT IM | Medium Descr | HEPB VACCINE ADULT 2/4 DOSE SCHEDULE FOR IM USE | Long Descr | Hepatitis B vaccine (HepB), CpG-adjuvanted, adult dosage, 2 dose or 4 dose schedule, for intramuscular use | Related Drugs | HEPLISAV-B | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Influenza, Pneumococcal Pneumonia, Hepatitis B, and Covid-19 Vaccines; Monoclonal Antibody Therapy Product | ASC Payment Indicator | Corneal tissue acquisition, hepatitis B vaccine; paid at reasonable cost. | Type of Service (TOS) | V - Pneumococcal/Flu Vaccine | Berenson-Eggers TOS (BETOS) | P6C - Minor procedures - other (Medicare fee schedule) | MUE | 1 | CCS Clinical Classification | 228 - Prophylactic vaccinations and inoculations |
| X1 | Continuous/broad services: for reporting services by clinicians, who provide the principal care for a patient, with no planned endpoint of the relationship; services in this category represent comprehensive care, dealing with the entire scope of patient problems, either directly or in a care coordination role; reporting clinician service examples include, but are not limited to: primary care, and clinicians providing comprehensive care to patients in addition to specialty care | GA | Waiver of liability statement issued as required by payer policy, individual case | SL | State supplied vaccine | UC | Medicaid level of care 12, as defined by each state | JZ | Zero drug amount discarded/not administered to any patient | 59 | Distinct procedural service: under certain circumstances, it may be necessary to indicate that a procedure or service was distinct or independent from other non-e/m services performed on the same day. modifier 59 is used to identify procedures/services, other than e/m services, that are not normally reported together, but are appropriate under the circumstances. documentation must support a different session, different procedure or surgery, different site or organ system, separate incision/excision, separate lesion, or separate injury (or area of injury in extensive injuries) not ordinarily encountered or performed on the same day by the same individual. however, when another already established modifier is appropriate it should be used rather than modifier 59. only if no more descriptive modifier is available, and the use of modifier 59 best explains the circumstances, should modifier 59 be used. note: modifier 59 should not be appended to an e/m service. to report a separate and distinct e/m service with a non-e/m service performed on the same date, see modifier 25. | 95 | Synchronous telemedicine service rendered via a real-time interactive audio and video telecommunications system: synchronous telemedicine service is defined as a real-time interaction between a physician or other qualified health care professional and a patient who is located at a distant site from the physician or other qualified health care professional. the totality of the communication of information exchanged between the physician or other qualified health care professional and the patient during the course of the synchronous telemedicine service must be of an amount and nature that would be sufficient to meet the key components and/or requirements of the same service when rendered via a face-to-face interaction. modifier 95 may only be appended to the services listed in appendix p. appendix p is the list of cpt codes for services that are typically performed face-to-face, but may be rendered via a real-time (synchronous) interactive audio and video telecommunications system. | CC | Procedure code change (use 'cc' when the procedure code submitted was changed either for administrative reasons or because an incorrect code was filed) | CR | Catastrophe/disaster related | GC | This service has been performed in part by a resident under the direction of a teaching physician | GW | Service not related to the hospice patient's terminal condition | GX | Notice of liability issued, voluntary under payer policy | GY | Item or service statutorily excluded, does not meet the definition of any medicare benefit or, for non-medicare insurers, is not a contract benefit | GZ | Item or service expected to be denied as not reasonable and necessary | Q6 | Service furnished under a fee-for-time compensation arrangement by a substitute physician or by a substitute physical therapist furnishing outpatient physical therapy services in a health professional shortage area, a medically underserved area, or a rural area | X3 | Episodic/broad services: for reporting services by clinicians who have broad responsibility for the comprehensive needs of the patient that is limited to a defined period and circumstance such as a hospitalization; reporting clinician service examples include but are not limited to the hospitalist's services rendered providing comprehensive and general care to a patient while admitted to the hospital | XU | Unusual non-overlapping service, the use of a service that is distinct because it does not overlap usual components of the main service |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2023-01-01 | Changed | First appearance of change(s) in codebook. |
| 2022-07-01 | Changed | Code changed. |
| 2019-01-01 | Changed | First appearance of change (FDA approval) in codebook. |
| 2017-11-09 | Changed | FDA approval granted. |
| 2016-01-01 | Changed | First appearance of change in codebook. |
| 2015-07-01 | Changed | Description Changed. FDA approval pending. |
| 2013-01-01 | Added | Added |
Get instant expert-level medical coding assistance.